Abstract
The complexity of the central nervous system (CNS) exposes it to a number of different diseases, often caused by only small variations in gene sequence or expression level. Antisense oligonucleotides and RNA interference-mediated therapies hold great promise for the treatment of CNS diseases in which neurodegeneration is linked to overproduction of endogenous protein or to synthesis of aberrant proteins coded by dominant mutant alleles. Nevertheless, difficulties related to the crossing of the blood-brain barrier, expression vectors, molecule design and to the choosing of the correct target, should be effectively solved. This review summarizes some of the most recent findings concerning the administration of potential nucleic acid-based therapeutic drugs, as well as the most promising studies performed both in vitro and in animal models of disease. Finally, some current clinical trials involving antisense oligonucleotides or silencing RNA for therapy of neurological disorders are illustrated. Results of current studies and clinical trials are exciting, and further results will be certainly reached with increasing knowledge of blood-brain barrier transporters, of genes involved in neurological disease and in new vectors for efficient delivery to brain.
Keywords: antisense oligonucleotides, rna interference, small interfering rna, brain cancer, genetic disorders, gene delivery tools, blood brain barrier, clinical trials
Current Drug Targets
Title: Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Volume: 6 Issue: 1
Author(s): A. Forte, M. Cipollaro, A. Cascino and U. Galderisi
Affiliation:
Keywords: antisense oligonucleotides, rna interference, small interfering rna, brain cancer, genetic disorders, gene delivery tools, blood brain barrier, clinical trials
Abstract: The complexity of the central nervous system (CNS) exposes it to a number of different diseases, often caused by only small variations in gene sequence or expression level. Antisense oligonucleotides and RNA interference-mediated therapies hold great promise for the treatment of CNS diseases in which neurodegeneration is linked to overproduction of endogenous protein or to synthesis of aberrant proteins coded by dominant mutant alleles. Nevertheless, difficulties related to the crossing of the blood-brain barrier, expression vectors, molecule design and to the choosing of the correct target, should be effectively solved. This review summarizes some of the most recent findings concerning the administration of potential nucleic acid-based therapeutic drugs, as well as the most promising studies performed both in vitro and in animal models of disease. Finally, some current clinical trials involving antisense oligonucleotides or silencing RNA for therapy of neurological disorders are illustrated. Results of current studies and clinical trials are exciting, and further results will be certainly reached with increasing knowledge of blood-brain barrier transporters, of genes involved in neurological disease and in new vectors for efficient delivery to brain.
Export Options
About this article
Cite this article as:
Forte A., Cipollaro M., Cascino A. and Galderisi U., Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases, Current Drug Targets 2005; 6 (1) . https://dx.doi.org/10.2174/1389450053344920
DOI https://dx.doi.org/10.2174/1389450053344920 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Kv1.5 Blockers for the Treatment of Atrial Fibrillation: Approaches to Optimization of Potency and Selectivity and Translation to In Vivo Pharmacology
Current Topics in Medicinal Chemistry Controlled Delivery of Biotechnological Products
Current Pharmaceutical Biotechnology Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Levosimendan: A Novel Agent in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Virgin Olive Oil and Hypertension
Current Vascular Pharmacology Editorial: Perioperative Pharmacological Management: From Prescription Medications to Dietary Supplements
Current Clinical Pharmacology Meta-Analysis of Creatine for Neuroprotection Against Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Adverse Reactions Induced by Minocycline: A Review of Literature
Current Drug Safety Biofunctional Peptides from Milk Proteins: Mineral Binding and Cytomodulatory Effects
Current Pharmaceutical Design Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Putative Role for Apelin in Pressure/Volume Homeostasis and Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Therapeutic Potential of Metabotropic GABA (GABAB) Receptors and their Effector Ion Channels
Central Nervous System Agents in Medicinal Chemistry Refractory Behçet’s Disease with Multi-organ Involvement - Learning from Failure
Current Rheumatology Reviews Biological Properties of Citrus Flavonoids Pertaining to Cancer and Inflammation
Current Medicinal Chemistry The Evolution of Pharmacological Treatment for Parkinsons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Involvement of the Endogenous Opioid System in Cannabinoid Responses
Current Medicinal Chemistry - Central Nervous System Agents Stearoyl-CoA Desaturase: A Vital Checkpoint in the Development and Progression of Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms of the Blunting of the Sympatho-Adrenal Response: A Theory
Current Diabetes Reviews Applications of Barton-McCombie Reaction in Total Syntheses
Current Organic Synthesis